《美股業績》芝加哥期權交易所(CBOE.US)季度純利升33% 期權日均成交量破紀錄
芝加哥期權交易所全球市場公司(CBOE.US)公布去年第四季業績,季度純利按年升33%至2.11億美元。每股季度攤薄純利1.98美元,經調整後為2.06美元。扣除收入成本及季度淨收益按年升9%至4.99億美元。
北美股票業務淨收益按年跌10%至8,630萬美元,期權分部市佔亦由34.1%降至33.5%。期權業務淨收益按年升15%至3.15億美元,日均期權成交合約達破紀錄的1,490萬份,其中指數期權成交升24%,標普500指數期權日均成交按年升22%至330萬份,波動指數期權成交按年升33%。
即日到期期權成交佔標普500指數期權活動45%,該比率於上月升至50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.